KRAS mutation occurs in 30% to 50% of colorectal cancers (CRCs) and has been
suggested to be associated with proliferation and decreased apoptosis. In this study, we …

Introduction Approximately 40% of colorectal cancers have a KRAS mutation. The
prognostic significance of KRAS mutations in patients with non-metastatic colon cancer has …

Simple Summary Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated colorectal
cancer (CRC) seems to have a different biological behavior and therapeutic approach …

While the incidence of sporadic early onset (defined here as≤ 40 years of age) colorectal
cancer is increasing, its molecular pathogenesis remains unclear. In particular, previous …

BACKGROUND The RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways all
belong to mitogen-activated protein kinase (MAPK) signaling pathways, Mutations in any …

Somatic KRAS mutation is an early well‐known event in colorectal carcinogenesis but a
complete understanding of RAS function and dysfunction in colorectal cancer is still to come …

OBJECTIVE: Mutation of the KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homologue) gene plays an important role in colorectal tumorigenesis. This study examined …

The aim of this study was to investigate the clinicopathological characteristics and
distribution by tumor localization of KRAS point mutations in metastatic colorectal cancer. A …

Objective KRAS gene mutations are a useful predictive factor for the efficacy of anti-
epidermal growth factor receptor therapeutics. Since there were no large-scale studies …

Background The optimal laboratory assay for detecting KRAS mutations in different
biospecimens from patients with metastatic colorectal cancer (mCRC), and the clinical …